Develops cancer drugs designed to carry radiation directly to cancer cells, for potential treatment of blood cancers and solid tumors in adults and children.
10-K for FY2025, filed Mar 4, 2026We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the…View ↗
The Company is primarily focused on the development of its radioconjugate PDC programs, also known as phospholipid radioconjugates or PRCs…View ↗
The CLOVER-2 Phase 1a pediatric study, an open-label, sequential-group, dose-escalation study, was conducted internationally at seven…View ↗
No revenue reported yet.
10-K for FY2025, filed Mar 4, 2026
10-Q for Q3 FY2026, filed Nov 10, 2026
−$8MView ↗
Pipeline emphasis
The older report described iopofosine as the lead, alongside a preclinical chemotherapy program, an alpha-emitter series and partnered assets. The latest report centers its pipeline on radioconjugates, including iopofosine and additional lead programs.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 4, 2026Our lead PDC therapeutic, iopofosine I 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer…View ↗
Our product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900), a PDC-based alpha-emitter radiotherapeutic…View ↗
We have leveraged our PDC platform to establish three ongoing collaborations featuring four unique payloads and mechanisms of action.…View ↗
The Company is primarily focused on the development of its radioconjugate PDC programs, also known as phospholipid radioconjugates or PRCs…View ↗
Loading...